Compare
CareDx, Inc. vs Fulgent Genetics, Inc. vs BillionToOne, Inc. vs Caris Life Sciences, Inc.
| Latest fiscal year | CareDx, Inc. CDNA | Fulgent Genetics, Inc. FLGT | BillionToOne, Inc. BLLN | Caris Life Sciences, Inc. CAI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $379.81M | $322.67M | $305.11M | $812.03M |
| Revenue growth (YoY) | +13.8% | +13.8% | +100.0% | +97.0% |
| Gross margin | n/a | 40.6% | 68.3% | n/a |
| Operating margin | -8.1% | -28.2% | 5.3% | 5.6% |
| Net margin | -5.6% | -18.8% | 2.4% | -8.4% |
| Net income | -$21.35M | -$60.51M | $7.45M | -$68.09M |
| EPS (Diluted) | -$0.40 | n/a | $0.14 | -$3.22 |
| Operating cash flow | $42.03M | -$101.64M | $24.59M | $83.16M |
| Free cash flow | n/a | -$124.21M | $15.71M | $66.89M |
| Cash & equivalents | $65.43M | $50.19M | $495.98M | $796.27M |
| Total assets | $413.23M | $1.21B | $632.65M | $1.13B |
| Total liabilities | $110.13M | $106.81M | $152.55M | $548.36M |
| Shareholders' equity | $303.10M | $1.11B | $480.11M | $577.31M |
| Return on year-end equity | -7.0% | -5.4% | 1.6% | -11.8% |
| Shares outstanding | 50.92M | 31.08M | n/a | 282.53M |
Revenue, most recent five fiscal years
| Fiscal year | CareDx, Inc. | Fulgent Genetics, Inc. | BillionToOne, Inc. | Caris Life Sciences, Inc. |
|---|---|---|---|---|
| Latest | $379.81M Ended 2025-12-31 | $322.67M Ended 2025-12-31 | $305.11M Ended 2025-12-31 | $812.03M Ended 2025-12-31 |
| 1 year earlier | $333.79M Ended 2024-12-31 | $283.47M Ended 2024-12-31 | $152.58M Ended 2024-12-31 | $412.26M Ended 2024-12-31 |
| 2 years earlier | $280.32M Ended 2023-12-31 | $289.21M Ended 2023-12-31 | $71.73M Ended 2023-12-31 | $306.13M Ended 2023-12-31 |
| 3 years earlier | $321.79M Ended 2022-12-31 | $618.97M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | $296.40M Ended 2021-12-31 | $992.58M Ended 2021-12-31 | n/a | n/a |